ReviewHuman vaccines & immunotherapeutics2013
Plasmodium vivax malaria vaccines: why are we where we are?
Review in Human vaccines & immunotherapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Naturally acquired antibodies toFrontiers in immunology · 2026Article
- Plasmodium vivax circumsporozoite surface protein (PvCSP) as a vaccine candidate: a brief review.Revista do Instituto de Medicina Tropical de Sao Paulo · 2025Review
- Immunogenicity of PvCyRPA, PvCelTOS and Pvs25 chimeric recombinant protein ofFrontiers in immunology · 2024Article
- Systems biology of malaria explored with nonhuman primates.Malaria journal · 2022Review
- Plasmodium vivax pre-erythrocytic vaccines.Parasitology international · 2021Review
- Global distribution of single amino acid polymorphisms inOpen biology · 2020Article
- Article
- Evaluation of antibody responses to the early transcribed membrane protein family in Plasmodium vivax.Parasites & vectors · 2019Article
- Tailoring a Plasmodium vivax Vaccine To Enhance Efficacy through a Combination of a CSP Virus-Like Particle and TRAP Viral Vectors.Infection and immunity · 2018Article
- Host Cell Tropism and Adaptation of Blood-Stage Malaria Parasites: Challenges for Malaria Elimination.Cold Spring Harbor perspectives in medicine · 2017Review
- Microcrystalline Tyrosine (MCTVaccines · 2017Article
- Article
- Rational development of a protective P. vivax vaccine evaluated with transgenic rodent parasite challenge models.Scientific reports · 2017Article
- Allele-specific antibodies to Plasmodium vivax merozoite surface protein-1: prevalence and inverse relationship to haemoglobin levels during infection.Malaria journal · 2016Article
- Acquisition and Longevity of Antibodies to Plasmodium vivax Preerythrocytic Antigens in Western Thailand.Clinical and vaccine immunology : CVI · 2016Article
- From within host dynamics to the epidemiology of infectious disease: Scientific overview and challenges.Mathematical biosciences · 2015Review
- Protective efficacy of a Plasmodium vivax circumsporozoite protein-based vaccine in Aotus nancymaae is associated with antibodies to the repeat region.PLoS neglected tropical diseases · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Malaria is one of the few diseases in which morbidity is still measured in hundreds of millions of cases every year. Plasmodium vivax and Plasmodium falciparum are responsible for nearly all the malaria cases in the world and despite difficulties in obtaining an exact number, estimates indicate an astonishing 349-552 million clinical cases of malaria due to P. falciparum in 2007 and between 132-391 million clinical episodes due to P. vivax in 2009. It is becoming evident that eradication of malaria will be an arduous task and P. vivax will be one of the most difficult species to eliminate and perhaps become the last standing malaria parasite. Indeed, in countries that succeed in decreasing the disease burden, nearly all the remaining malaria cases are caused by P. vivax. Such resilience is mainly due to the sophisticated mechanism that the parasite has evolved to remain dormant for months or years forming hypnozoites, a small structure in the liver that will be a major hurdle in the efforts toward malaria eradication. Furthermore, while clinical trials of vaccines against P. falciparum are making fast progress, a very different picture is seen with P. vivax, where only few candidates are currently active in clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.